Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.
about
Thrombopoietin as biomarker and mediator of cardiovascular damage in critical diseasesImmune thrombocytopeniaContemporary management of primary immune thrombocytopenia in adultsChildhood immune thrombocytopenia: Clinical presentation and managementThe Centenary of Immune Thrombocytopenia - Part 1: Revising Nomenclature and PathogenesisThe pathogenesis of immune thrombocytopaenic purpuraThromboembolism in adults with primary immune thrombocytopenia: a systematic literature review and meta-analysis.Inflammation induces hemorrhage in thrombocytopenia.Numerical analysis of in vivo platelet consumption data from ITP patientsManagement of patients with refractory immune thrombocytopenic purpura.An open-label, unit dose-finding study of AMG 531, a novel thrombopoiesis-stimulating peptibody, in patients with immune thrombocytopenic purpura.Abnormalities in the expression of CD55 and CD59 surface molecules on peripheral blood cells are not specific to paroxysmal nocturnal hemoglobinuria.Nitric oxide in immune thrombocytopenic purpura.The ITP syndrome: pathogenic and clinical diversity.Thromboembolic events among adult patients with primary immune thrombocytopenia in the United Kingdom General Practice Research DatabaseAssessment of immunogenicity of romiplostim in clinical studies with ITP subjectsManagement of chronic immune thrombocytopenic purpura: targeting insufficient megakaryopoiesis as a novel therapeutic principleToxicities of the thrombopoietic growth factorsPopulation pharmacokinetics of eltrombopag in healthy subjects and patients with chronic idiopathic thrombocytopenic purpura.The maternal immune response to fetal platelet GPIbα causes frequent miscarriage in mice that can be prevented by intravenous IgG and anti-FcRn therapies.[Primary immune thrombocytopenia in adults: diagnostics and treatment consensus statement of the Austrian Society of Hematology and Oncology (ÖGHO)].A lower starting dose of eltrombopag is efficacious in Japanese patients with previously treated chronic immune thrombocytopenia.Romiplostim for the treatment of primary immune thrombocytopenia.Eltrombopag: the emerging evidence of its therapeutic value in thrombocytopeniaDecreased plasma cytokines are associated with low platelet counts in aplastic anemia and immune thrombocytopenic purpura.Management of children and adolescents with primary immune thrombocytopenia: controversies and solutions.Platelet count kinetics following interruption of antiretroviral treatment.Splenectomy as a curative treatment for immune thrombocytopenia: a retrospective analysis of 233 patients with a minimum follow up of 10 years.Adverse postoperative outcomes in surgical patients with immune thrombocytopenia.Hemostatic challenges in patients with chronic immune thrombocytopenia treated with eltrombopagWaiting for platelet counts causes unsubstantiated delay of thrombolysis therapy.Splenectomy and the incidence of venous thromboembolism and sepsis in patients with immune thrombocytopeniaThrombopoietin receptor agonists in primary immune thrombocytopenia.Immune thrombocytopenia -- what are the new treatment options?Thrombopoietin levels in patients with disorders of platelet production: diagnostic potential and utility in predicting response to TPO receptor agonists.Long-term safety and tolerability of romiplostim in patients with primary immune thrombocytopenia: a pooled analysis of 13 clinical trials.Romiplostim as early treatment for refractory primary immune thrombocytopenia.Dental procedures in 24 patients with chronic immune thrombocytopenia in prospective clinical studies of eltrombopag.Thrombotic risk in patients with primary immune thrombocytopenia is only mildly increased and explained by personal and treatment-related risk factors.The pharmacology and clinical application of thrombopoietin receptor agonists.
P2860
Q21296645-66D94B8C-4015-4C38-B8FE-166A653E4818Q26830918-79C525C4-8077-47BF-B269-7E178E8AC851Q26853680-EE03E192-8DF7-4E76-9DE2-540D8BE92065Q27023294-22A69116-2F4C-47CF-8B0D-2445863E8902Q28068881-36B0E501-A5C5-45E5-9C06-B871B50689BDQ28236898-FEAC77F1-A6D6-48B5-8FB2-7F28F3286F64Q30250259-B7A74687-4CAB-45E7-A0D4-052120EB0A0AQ30481913-E745160A-DE68-4877-9CA6-D75DF593862AQ31010919-A3C18E93-F068-474B-98AC-178837F51D98Q33372113-99E8C80E-A4A9-4F00-B50B-D0DA03D68714Q33373074-2FDF372B-E542-4FC8-868E-593FB7571AB3Q33382851-A5CE18EC-514D-4F7A-B2F7-2BDD0A42004AQ33382856-67CBC2CE-C24B-477A-8591-8AD28E667365Q33384235-BEEDD826-7A8A-48B8-BC96-2E2CE4761DCCQ33388213-93D28602-B8CC-4AF6-9A6B-F969725B5C53Q33388267-3182126C-E411-4F8E-9C5F-BD4E0EC30AB5Q33390001-EE2F5BDC-A034-49AE-B1EA-1A2F7488131AQ33390645-51DB3251-16D4-4784-9740-8DCCC4238F44Q33391013-B59A9A82-A225-4769-AB2D-04D19B024392Q33397768-716F3CCE-0A3F-41EF-B6AA-FE5B399A3650Q33400018-04F99962-975A-4356-9187-1E25A7F6EB70Q33400203-82AB16CE-91F7-444B-B82A-93ADC5F37200Q33400560-0705BE97-2D40-46F3-8E46-102BB3B25800Q33400722-2AA05815-6D96-46E7-8395-44E2B81FB87BQ33400949-FD3A240B-5DFF-49C4-8939-07ACD7197540Q33402387-A2BEB379-A2D3-48B2-BDE1-3100B9DE3BDEQ33403565-BCAA2CD3-0EE3-429F-94DB-77C11E6BFAFFQ33404320-F10FDE4C-2840-4772-89C7-2201D4A4EBFFQ33405515-A0FCB10F-BE6F-4E7F-A4D0-63A7B0667DE1Q33405820-D2A5E3A9-8DB2-4890-BDC9-A15B3DA670EBQ33406778-E501898C-FA5A-4AAC-8032-9DB0B1DCCA04Q33407451-E5098474-5602-40A3-B56B-BD496BDB2F7FQ33407623-7BC7ADF8-B8AD-4F35-BA64-221813CC0A42Q33407802-C297C504-58A8-4F12-9C1D-F50A9A5DE6CBQ33409528-C2460B7C-FDEA-4984-8B4C-C923931BF743Q33409611-02586DEF-898A-40A1-B300-38C6C7CB009DQ33410572-95ECC9B4-CB27-48B5-8F24-2DB4EC18D4CAQ33412710-17A8BB25-6A39-4B5E-A4B4-77B2B74AC161Q33415996-CA11E646-9DA4-43A4-BDBF-FA6382F18A9BQ33417700-CE656CFD-CBC3-4C1F-BE9E-002E28874556
P2860
Prospective screening of 205 patients with ITP, including diagnosis, serological markers, and the relationship between platelet counts, endogenous thrombopoietin, and circulating antithrombopoietin antibodies.
description
2004 nî lūn-bûn
@nan
2004 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@ast
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@en
type
label
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@ast
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@en
prefLabel
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@ast
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@en
P2093
P356
P1476
Prospective screening of 205 p ...... antithrombopoietin antibodies.
@en
P2093
Catherine P M Hayward
ITP Study Group
Janet L Nichol
Louis M Aledort
Mon-Gy Chen
P304
P356
10.1002/AJH.20104
P577
2004-07-01T00:00:00Z